Our top pick for
Atreca, Inc is a biotechnology business based in the US. Atreca shares (BCEL) are listed on the NASDAQ and all prices are listed in US Dollars. Atreca employs 130 staff and has a market cap (total outstanding shares value) of USD$641.6 million.
|52-week range||USD$10.8807 - USD$27.89|
|50-day moving average||USD$16.3781|
|200-day moving average||USD$15.0669|
|Wall St. target price||USD$30|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-18.879|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Atreca stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Atreca's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Atreca's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Atreca shares trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$0|
|Return on assets TTM||-23.75%|
|Return on equity TTM||-40.25%|
|Market capitalisation||USD$641.6 million|
TTM: trailing 12 months
There are currently 3.4 million Atreca shares held short by investors – that's known as Atreca's "short interest". This figure is 7.4% up from 3.2 million last month.
There are a few different ways that this level of interest in shorting Atreca shares can be evaluated.
Atreca's "short interest ratio" (SIR) is the quantity of Atreca shares currently shorted divided by the average quantity of Atreca shares traded daily (recently around 287313.64016736). Atreca's SIR currently stands at 11.95. In other words for every 100,000 Atreca shares traded daily on the market, roughly 11950 shares are currently held short.
However Atreca's short interest can also be evaluated against the total number of Atreca shares, or, against the total number of tradable Atreca shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atreca's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Atreca shares in existence, roughly 90 shares are currently held short) or 0.156% of the tradable shares (for every 100,000 tradable Atreca shares, roughly 156 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Atreca.
Find out more about how you can short Atreca stock.
We're not expecting Atreca to pay a dividend over the next 12 months.
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in clinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a strategic research collaboration with Merck Sharp & Dohme Corp. to identify the antigenic targets of select antibodies discovered with potential utility in oncology. Atreca, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Everything we know about the Reddit IPO, plus information on how to buy in.
Everything we know about the Hayward Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Alignment Healthcare Inc IPO, plus information on how to buy in.
Everything we know about the Olink Holding AB (publ) IPO, plus information on how to buy in.
Everything we know about the Procore IPO, plus information on how to buy in.
Everything we know about the Navios South American Logistics Inc IPO, plus information on how to buy in.
Everything we know about the Lava Therapeutics IPO, plus information on how to buy in.
Everything we know about the Pop Culture Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Bukalapak IPO, plus information on how to buy in.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.